Worsening of motor features of Parkinsonism with olanzapine
Identifieur interne : 002F66 ( Istex/Corpus ); précédent : 002F65; suivant : 002F67Worsening of motor features of Parkinsonism with olanzapine
Auteurs : Eric S. Molho ; Stewart A. FactorSource :
- Movement Disorders [ 0885-3185 ] ; 1999-11.
English descriptors
- KwdEn :
Abstract
Clozapine is the current treatment of choice for drug‐induced psychosis (DIP) occurring in Parkinson's disease. However, alternative medications have been sought because of the small but significant risk of agranulocytosis and the need for frequent blood testing. The new “atypical” antipsychotic olanzapine (OLZ) has recently been proposed as a safe and effective option for treating psychosis in this setting. To investigate this, we retrospectively evaluated all 12 of our patients treated with OLZ for DIP. Symptoms of psychosis were improved in nine of 12 patients, but nine of 12 patients also experienced worsening of motor functioning while on OLZ. The worsening was considered dramatic in six of these patients. Overall, there was no significant increase in levodopa doses on OLZ. Only one patient remained on OLZ at the time of the analysis. Nine patients were switched to alternative treatment for DIP. We conclude that although OLZ may improve symptoms of psychosis in parkinsonian patients, it can also worsen motor functioning. In some patients, the degree of motor worsening may be intolerable.
Url:
DOI: 10.1002/1531-8257(199911)14:6<1014::AID-MDS1017>3.0.CO;2-9
Links to Exploration step
ISTEX:295A7D8B0347294665D08E59C403C706A45CC210Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Worsening of motor features of Parkinsonism with olanzapine</title><author><name sortKey="Molho, Eric S" sort="Molho, Eric S" uniqKey="Molho E" first="Eric S." last="Molho">Eric S. Molho</name><affiliation><mods:affiliation>Department of Neurology, Albany Medical College, Albany, New York, U.S.A.</mods:affiliation></affiliation></author><author><name sortKey="Factor, Stewart A" sort="Factor, Stewart A" uniqKey="Factor S" first="Stewart A." last="Factor">Stewart A. Factor</name><affiliation><mods:affiliation>Department of Neurology, Albany Medical College, Albany, New York, U.S.A.</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:295A7D8B0347294665D08E59C403C706A45CC210</idno><date when="1999" year="1999">1999</date><idno type="doi">10.1002/1531-8257(199911)14:6<1014::AID-MDS1017>3.0.CO;2-9</idno><idno type="url">https://api.istex.fr/document/295A7D8B0347294665D08E59C403C706A45CC210/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">002F66</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Worsening of motor features of Parkinsonism with olanzapine</title><author><name sortKey="Molho, Eric S" sort="Molho, Eric S" uniqKey="Molho E" first="Eric S." last="Molho">Eric S. Molho</name><affiliation><mods:affiliation>Department of Neurology, Albany Medical College, Albany, New York, U.S.A.</mods:affiliation></affiliation></author><author><name sortKey="Factor, Stewart A" sort="Factor, Stewart A" uniqKey="Factor S" first="Stewart A." last="Factor">Stewart A. Factor</name><affiliation><mods:affiliation>Department of Neurology, Albany Medical College, Albany, New York, U.S.A.</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>John Wiley & Sons, Inc.</publisher><pubPlace>New York</pubPlace><date type="published" when="1999-11">1999-11</date><biblScope unit="vol">14</biblScope><biblScope unit="issue">6</biblScope><biblScope unit="page" from="1014">1014</biblScope><biblScope unit="page" to="1016">1016</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">295A7D8B0347294665D08E59C403C706A45CC210</idno><idno type="DOI">10.1002/1531-8257(199911)14:6<1014::AID-MDS1017>3.0.CO;2-9</idno><idno type="ArticleID">MDS1017</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Olanzapine</term><term>Parkinsonism</term><term>Psychosis</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Clozapine is the current treatment of choice for drug‐induced psychosis (DIP) occurring in Parkinson's disease. However, alternative medications have been sought because of the small but significant risk of agranulocytosis and the need for frequent blood testing. The new “atypical” antipsychotic olanzapine (OLZ) has recently been proposed as a safe and effective option for treating psychosis in this setting. To investigate this, we retrospectively evaluated all 12 of our patients treated with OLZ for DIP. Symptoms of psychosis were improved in nine of 12 patients, but nine of 12 patients also experienced worsening of motor functioning while on OLZ. The worsening was considered dramatic in six of these patients. Overall, there was no significant increase in levodopa doses on OLZ. Only one patient remained on OLZ at the time of the analysis. Nine patients were switched to alternative treatment for DIP. We conclude that although OLZ may improve symptoms of psychosis in parkinsonian patients, it can also worsen motor functioning. In some patients, the degree of motor worsening may be intolerable.</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>Eric S. Molho MD</name><affiliations><json:string>Department of Neurology, Albany Medical College, Albany, New York, U.S.A.</json:string></affiliations></json:item><json:item><name>Stewart A. Factor DO</name><affiliations><json:string>Department of Neurology, Albany Medical College, Albany, New York, U.S.A.</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>Parkinsonism</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Psychosis</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Olanzapine</value></json:item></subject><language><json:string>eng</json:string></language><abstract>Clozapine is the current treatment of choice for drug‐induced psychosis (DIP) occurring in Parkinson's disease. However, alternative medications have been sought because of the small but significant risk of agranulocytosis and the need for frequent blood testing. The new “atypical” antipsychotic olanzapine (OLZ) has recently been proposed as a safe and effective option for treating psychosis in this setting. To investigate this, we retrospectively evaluated all 12 of our patients treated with OLZ for DIP. Symptoms of psychosis were improved in nine of 12 patients, but nine of 12 patients also experienced worsening of motor functioning while on OLZ. The worsening was considered dramatic in six of these patients. Overall, there was no significant increase in levodopa doses on OLZ. Only one patient remained on OLZ at the time of the analysis. Nine patients were switched to alternative treatment for DIP. We conclude that although OLZ may improve symptoms of psychosis in parkinsonian patients, it can also worsen motor functioning. In some patients, the degree of motor worsening may be intolerable.</abstract><qualityIndicators><score>4.031</score><pdfVersion>1.3</pdfVersion><pdfPageSize>612 x 792 pts (letter)</pdfPageSize><refBibsNative>true</refBibsNative><abstractCharCount>1109</abstractCharCount><pdfWordCount>1979</pdfWordCount><pdfCharCount>12584</pdfCharCount><pdfPageCount>3</pdfPageCount><abstractWordCount>171</abstractWordCount></qualityIndicators><title>Worsening of motor features of Parkinsonism with olanzapine</title><genre><json:string>Serial article</json:string></genre><host><volume>14</volume><pages><total>3</total><last>1016</last><first>1014</first></pages><issn><json:string>0885-3185</json:string></issn><issue>6</issue><subject><json:item><value>Brief Report</value></json:item></subject><genre></genre><language><json:string>unknown</json:string></language><title>Movement Disorders</title><doi><json:string>10.1002/(ISSN)1531-8257</json:string></doi></host><publicationDate>1999</publicationDate><copyrightDate>1999</copyrightDate><doi><json:string>10.1002/1531-8257(199911)14:6>1014::AID-MDS1017>3.0.CO;2-9</json:string></doi><id>295A7D8B0347294665D08E59C403C706A45CC210</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/295A7D8B0347294665D08E59C403C706A45CC210/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/295A7D8B0347294665D08E59C403C706A45CC210/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/295A7D8B0347294665D08E59C403C706A45CC210/fulltext/tei"><teiHeader type="text"><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Worsening of motor features of Parkinsonism with olanzapine</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>John Wiley & Sons, Inc.</publisher><pubPlace>New York</pubPlace><availability><p>John Wiley & Sons, Inc.</p></availability><date>1999</date></publicationStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Worsening of motor features of Parkinsonism with olanzapine</title><author><persName><forename type="first">Eric S.</forename><surname>Molho</surname><roleName type="degree">MD</roleName></persName><affiliation>Department of Neurology, Albany Medical College, Albany, New York, U.S.A.</affiliation></author><author><persName><forename type="first">Stewart A.</forename><surname>Factor</surname><roleName type="degree">DO</roleName></persName><note type="correspondence"><p>Correspondence: Parkinson's Disease and Movement Disorders Center of Albany Medical Center, 215 Washington Avenue Extension, Albany, New York 12203, U.S.A.</p></note><affiliation>Department of Neurology, Albany Medical College, Albany, New York, U.S.A.</affiliation></author></analytic><monogr><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="pISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><idno type="DOI">10.1002/(ISSN)1531-8257</idno><imprint><publisher>John Wiley & Sons, Inc.</publisher><pubPlace>New York</pubPlace><date type="published" when="1999-11"></date><biblScope unit="vol">14</biblScope><biblScope unit="issue">6</biblScope><biblScope unit="page" from="1014">1014</biblScope><biblScope unit="page" to="1016">1016</biblScope></imprint></monogr><idno type="istex">295A7D8B0347294665D08E59C403C706A45CC210</idno><idno type="DOI">10.1002/1531-8257(199911)14:6<1014::AID-MDS1017>3.0.CO;2-9</idno><idno type="ArticleID">MDS1017</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>1999</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>Clozapine is the current treatment of choice for drug‐induced psychosis (DIP) occurring in Parkinson's disease. However, alternative medications have been sought because of the small but significant risk of agranulocytosis and the need for frequent blood testing. The new “atypical” antipsychotic olanzapine (OLZ) has recently been proposed as a safe and effective option for treating psychosis in this setting. To investigate this, we retrospectively evaluated all 12 of our patients treated with OLZ for DIP. Symptoms of psychosis were improved in nine of 12 patients, but nine of 12 patients also experienced worsening of motor functioning while on OLZ. The worsening was considered dramatic in six of these patients. Overall, there was no significant increase in levodopa doses on OLZ. Only one patient remained on OLZ at the time of the analysis. Nine patients were switched to alternative treatment for DIP. We conclude that although OLZ may improve symptoms of psychosis in parkinsonian patients, it can also worsen motor functioning. In some patients, the degree of motor worsening may be intolerable.</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>Keywords</head><item><term>Parkinsonism</term></item><item><term>Psychosis</term></item><item><term>Olanzapine</term></item></list></keywords></textClass><textClass><keywords scheme="Journal Subject"><list><head>Article category</head><item><term>Brief Report</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="1999-03-31">Received</change><change when="1999-07-14">Registration</change><change when="1999-11">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/295A7D8B0347294665D08E59C403C706A45CC210/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>John Wiley & Sons, Inc.</publisherName><publisherLoc>New York</publisherLoc></publisherInfo><doi registered="yes">10.1002/(ISSN)1531-8257</doi><issn type="print">0885-3185</issn><issn type="electronic">1531-8257</issn><idGroup><id type="product" value="MDS"></id></idGroup><titleGroup><title type="main" xml:lang="en" sort="MOVEMENT DISORDERS">Movement Disorders</title><title type="subtitle">Official Journal of the Movement Disorder Society</title><title type="short">Mov. Disord.</title></titleGroup></publicationMeta><publicationMeta level="part" position="60"><doi origin="wiley" registered="yes">10.1002/1531-8257(199911)14:6<>1.0.CO;2-Q</doi><numberingGroup><numbering type="journalVolume" number="14">14</numbering><numbering type="journalIssue">6</numbering></numberingGroup><coverDate startDate="1999-11">November 1999</coverDate></publicationMeta><publicationMeta level="unit" type="shortCommunication" position="17" status="forIssue"><doi origin="wiley" registered="yes">10.1002/1531-8257(199911)14:6<1014::AID-MDS1017>3.0.CO;2-9</doi><idGroup><id type="unit" value="MDS1017"></id></idGroup><countGroup><count type="pageTotal" number="3"></count></countGroup><titleGroup><title type="articleCategory">Brief Report</title><title type="tocHeading1">Brief Reports</title></titleGroup><copyright ownership="thirdParty">Copyright © 1999 Movement Disorder Society</copyright><eventGroup><event type="manuscriptReceived" date="1999-03-31"></event><event type="manuscriptRevised" date="1999-07-07"></event><event type="manuscriptAccepted" date="1999-07-14"></event><event type="firstOnline" date="2001-01-25"></event><event type="publishedOnlineFinalForm" date="2001-01-25"></event><event type="xmlConverted" agent="Converter:JWSART34_TO_WML3G version:2.3.2 mode:FullText source:HeaderRef result:HeaderRef" date="2010-03-09"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-02-02"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-31"></event></eventGroup><numberingGroup><numbering type="pageFirst">1014</numbering><numbering type="pageLast">1016</numbering></numberingGroup><correspondenceTo>Parkinson's Disease and Movement Disorders Center of Albany Medical Center, 215 Washington Avenue Extension, Albany, New York 12203, U.S.A.</correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:MDS.MDS1017.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="0"></count><count type="tableTotal" number="1"></count><count type="referenceTotal" number="16"></count><count type="wordTotal" number="1887"></count></countGroup><titleGroup><title type="main" xml:lang="en">Worsening of motor features of Parkinsonism with olanzapine</title><title type="short" xml:lang="en">Worsening Parkinson's Disease with Olanzapine</title></titleGroup><creators><creator xml:id="au1" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Eric S.</givenNames><familyName>Molho</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au2" creatorRole="author" affiliationRef="#af1" corresponding="yes"><personName><givenNames>Stewart A.</givenNames><familyName>Factor</familyName><degrees>DO</degrees></personName></creator></creators><affiliationGroup><affiliation xml:id="af1" countryCode="US" type="organization"><unparsedAffiliation>Department of Neurology, Albany Medical College, Albany, New York, U.S.A.</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en" type="author"><keyword xml:id="kwd1">Parkinsonism</keyword><keyword xml:id="kwd2">Psychosis</keyword><keyword xml:id="kwd3">Olanzapine</keyword></keywordGroup><abstractGroup><abstract type="main" xml:lang="en"><title type="main">Abstract</title><p>Clozapine is the current treatment of choice for drug‐induced psychosis (DIP) occurring in Parkinson's disease. However, alternative medications have been sought because of the small but significant risk of agranulocytosis and the need for frequent blood testing. The new “atypical” antipsychotic olanzapine (OLZ) has recently been proposed as a safe and effective option for treating psychosis in this setting. To investigate this, we retrospectively evaluated all 12 of our patients treated with OLZ for DIP. Symptoms of psychosis were improved in nine of 12 patients, but nine of 12 patients also experienced worsening of motor functioning while on OLZ. The worsening was considered dramatic in six of these patients. Overall, there was no significant increase in levodopa doses on OLZ. Only one patient remained on OLZ at the time of the analysis. Nine patients were switched to alternative treatment for DIP. We conclude that although OLZ may improve symptoms of psychosis in parkinsonian patients, it can also worsen motor functioning. In some patients, the degree of motor worsening may be intolerable.</p></abstract></abstractGroup></contentMeta></header></component></istex:document></istex:metadataXml><!--Version 0.6 générée le 3-12-2015--><mods version="3.6"><titleInfo lang="en"><title>Worsening of motor features of Parkinsonism with olanzapine</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>Worsening Parkinson's Disease with Olanzapine</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Worsening of motor features of Parkinsonism with olanzapine</title></titleInfo><name type="personal"><namePart type="given">Eric S.</namePart><namePart type="family">Molho</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Neurology, Albany Medical College, Albany, New York, U.S.A.</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Stewart A.</namePart><namePart type="family">Factor</namePart><namePart type="termsOfAddress">DO</namePart><affiliation>Department of Neurology, Albany Medical College, Albany, New York, U.S.A.</affiliation><description>Correspondence: Parkinson's Disease and Movement Disorders Center of Albany Medical Center, 215 Washington Avenue Extension, Albany, New York 12203, U.S.A.</description><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre authority="originalCategForm">shortCommunication</genre><originInfo><publisher>John Wiley & Sons, Inc.</publisher><place><placeTerm type="text">New York</placeTerm></place><dateIssued encoding="w3cdtf">1999-11</dateIssued><dateCaptured encoding="w3cdtf">1999-03-31</dateCaptured><dateValid encoding="w3cdtf">1999-07-14</dateValid><copyrightDate encoding="w3cdtf">1999</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="tables">1</extent><extent unit="references">16</extent><extent unit="words">1887</extent></physicalDescription><abstract lang="en">Clozapine is the current treatment of choice for drug‐induced psychosis (DIP) occurring in Parkinson's disease. However, alternative medications have been sought because of the small but significant risk of agranulocytosis and the need for frequent blood testing. The new “atypical” antipsychotic olanzapine (OLZ) has recently been proposed as a safe and effective option for treating psychosis in this setting. To investigate this, we retrospectively evaluated all 12 of our patients treated with OLZ for DIP. Symptoms of psychosis were improved in nine of 12 patients, but nine of 12 patients also experienced worsening of motor functioning while on OLZ. The worsening was considered dramatic in six of these patients. Overall, there was no significant increase in levodopa doses on OLZ. Only one patient remained on OLZ at the time of the analysis. Nine patients were switched to alternative treatment for DIP. We conclude that although OLZ may improve symptoms of psychosis in parkinsonian patients, it can also worsen motor functioning. In some patients, the degree of motor worsening may be intolerable.</abstract><subject lang="en"><genre>Keywords</genre><topic>Parkinsonism</topic><topic>Psychosis</topic><topic>Olanzapine</topic></subject><relatedItem type="host"><titleInfo><title>Movement Disorders</title><subTitle>Official Journal of the Movement Disorder Society</subTitle></titleInfo><titleInfo type="abbreviated"><title>Mov. Disord.</title></titleInfo><subject><genre>article category</genre><topic>Brief Report</topic></subject><identifier type="ISSN">0885-3185</identifier><identifier type="eISSN">1531-8257</identifier><identifier type="DOI">10.1002/(ISSN)1531-8257</identifier><identifier type="PublisherID">MDS</identifier><part><date>1999</date><detail type="volume"><caption>vol.</caption><number>14</number></detail><detail type="issue"><caption>no.</caption><number>6</number></detail><extent unit="pages"><start>1014</start><end>1016</end><total>3</total></extent></part></relatedItem><identifier type="istex">295A7D8B0347294665D08E59C403C706A45CC210</identifier><identifier type="DOI">10.1002/1531-8257(199911)14:6<1014::AID-MDS1017>3.0.CO;2-9</identifier><identifier type="ArticleID">MDS1017</identifier><accessCondition type="use and reproduction" contentType="copyright">Copyright © 1999 Movement Disorder Society</accessCondition><recordInfo><recordOrigin>John Wiley & Sons, Inc.</recordOrigin><recordContentSource>WILEY</recordContentSource></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002F66 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 002F66 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:295A7D8B0347294665D08E59C403C706A45CC210
|texte= Worsening of motor features of Parkinsonism with olanzapine
}}
| This area was generated with Dilib version V0.6.23. |  |